相关实验视频

Updated: Jun 10, 2025

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

在复发性复发性多发性硬化症中,克拉迪片首选向B细胞

Francesca Ammoscato¹, Mohammad Wafa², Justyna Skonieczna¹

¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Clinical immunology (Orlando, Fla.)

|October 20, 2024

概括

克拉迪宾片 (CladT) 通过耗尽记忆B细胞,有效地管理复发性复发性多发性硬化症 (RRMS). 这种治疗导致了脑内抗体产生和脑脊液中关键炎症标志物的持续减少.

科学领域:

神经免疫学神经免疫学
药理学药理学是指药理学的学科.

背景情况:

B细胞在多发性硬化症 (MS) 发病过程中起着至关重要的作用.
针对B细胞的疗法在控制MS活动方面表现出有效性.

研究的目的:

为量化边缘免疫细胞的时间变化及其在96周的克拉迪宾片 (CladT) 在复发性复发性多发性硬化症 (RRMS) 治疗期间的活动.
为了比较免疫细胞概况的变化与历史的阿勒姆图祖马布治疗队列.

主要方法:

十名RRMS参与者接受了CladT,血液样本以多次间隔收集至96周.
进行了免疫细胞分析,脑脊液 (CSF) 分析,临床和脑成像评估.
与用阿勒姆图祖马布治疗的历史队列进行比较.

主要成果:

CladT主要消耗了记忆B细胞和抗体分泌细胞前体.
在卡帕自由轻链指数 (kFLC),IgG指数和CSF CXCL-13水平上观察到显著的减少.
在48周后,CSF NfL水平也降低了,这表明神经炎症的减少.

结论:

在RRMS患者中,CladT治疗会对内抗体产生和总IgG产生持续影响.
观察到的CSF CXCL-13和NfL的减少表明对中枢神经系统炎症有显著影响.
在管理RRMS活动方面,CladT表现出有利的免疫调节特征.

关键词:

生物标志物生物标志物大脑脊髓液中的脑脊液.克拉德里宾 (cladribine) 是一种药物.多发性硬化症是一种多发性硬化症.周边免疫细胞是周边免疫细胞.

更多相关视频

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...